At the 131st Congress of the French Society of Ophthalmology in Paris, France, the role of second-generation intravitreal anti-VEGF injections compared to corticosteroid injections in treating diabetic macularedema (DME) was discussed. Both treatments are recommended as first-line options, but when both are available, Audrey Giocanti-Aurégan, MD, PhD, from Avicenne Hospital, AP-HP, Bobigny, France, advised that biomarkers identified through optical coherence tomography (OCT) should guide treatment decisions.

“Imaging provides insights into the potentially inflammatory nature of the edema,” she explained, noting that in such cases, corticosteroid treatment may be more appropriate.

Several structural biomarkers of the retina have been identified to predict the response to anti-VEGF or co

See Full Page